The first objective test for trauma in the brain.
Today's standard for PTSD is a questionnaire. DatChem-PTSD objectively records dysfunctional neural pathways, and monitors a patient's response to medication and therapy.
A subjective answer to an objective injury.
Approximately 10–12% of women will experience PTSD, twice the rate of men.
That higher burden owes to greater exposure to high-impact trauma such as sexual assault, violence, or service in the Defence Force. Yet today's assessment is a questionnaire, subjective, self-reported, and easily masked. DatChem makes it objective.
- A measured signal. Dysfunctional neural pathways, read directly from a standard MRI.
- Twice the burden. Women experience PTSD at roughly double the rate of men.
- Beyond the questionnaire. Objective evidence in place of self-report alone.
Recording the pathways trauma leaves behind.
DatChem-PTSD turns an MRI into an objective instrument for trauma, measuring the brain, then measuring it again as treatment unfolds.
Five pathways, or three
Records up to five dysfunctional neural pathways in women with PTSD, and three in men.
Response over time
Tracks the response, or the lack of it, to therapy, scan after scan, as treatment progresses.
Objective, not subjective
A measured biomarker rather than a self-reported score, evidence a clinician can act on.
From scan to report, on existing scanners.
DatChem-PTSD adds a short sequence to a standard MRI, no new hardware, with results returned to the physician in minutes.
Patient scan
A short sequence on a standard MRI captures the raw spectral data, no contrast, no biopsy.
Data capture
Raw data is transmitted securely from the scanner to the DatChem cloud.
Data processing
The chemical signature is extracted and compared against our exclusive databases.
Physician report
A report reaches the physician in minutes, mapping the pathways involved.
Validated in a completed trial.
A clinical trial funded by the USA CTTSO, the Combating Terrorism Technical Support Office, has been completed.
The work establishes DatChem-PTSD as an objective biomarker test for post-traumatic stress: recording the dysfunctional neural pathways characteristic of PTSD, and tracking how they respond to medication and therapy over time.
A path to ADHD.
The same approach extends beyond trauma. An ADHD clinical trial is next, beginning in Australia, with intent to progress globally.
ADHD trial next
An ADHD clinical trial is the next step for the platform, building directly on the PTSD work.
Australia, then global
Beginning in Australia, with the intent to progress globally as the evidence builds.
Patented spectroscopy
The underlying spectroscopy is patented, including ADHD spectral detection.
DatChem's technologies are undergoing regulatory evaluation (TGA, FDA and EMA) and are not yet approved for routine clinical use in all markets.
Bring DatChem-PTSD to your centre.
For clinical, research or partnership enquiries about DatChem-PTSD, we'd be glad to hear from you.